The association between breast cancer patients’ general health perception and organizational characteristics of the hospital

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e17523-e17523
Author(s):  
H. Pfaff ◽  
P. Steffen ◽  
A. Nitzsche ◽  
C. Kowalski

e17523 Background: The purpose of this study is to investigate the impact of organizational characteristics of the hospital on general health perception in postoperative primary breast cancer patients after discharge from hospital. Methods: Patients undergoing treatment for primary breast cancer in all certified breast centers in North Rhine-Westphalia (Germany) were invited to self-administer a questionnaire on health-related quality of life after discharge. Survey period was February to July 2007. 3,285 patients from 94 hospitals returned the questionnaire. The data were supplemented by disease and treatment characteristics reported by the oncologists (e.g. TNM-classification, type of surgery). Patient data were combined with information on hospital characteristics provided by hospital administrators. A multilevel analysis was applied to analyse the impact of organizational characteristics of the hospital (no. of annual breast cancer surgeries, breast care nurses employed, teaching hospital) on general health perception as reported by the breast cancer patients after discharge. Analyses were controlled for sociodemographic variables (age, marital status, education), type of surgery (mastectomy vs. BCT), and severity of disease (TNM-classification). Results: In the multilevel analysis performed organizational characteristics of the hospital do not contribute to patients’ general health after discharge. Only the variable “breast care nurses employed” is close to being positively associated with better general health at p < 0.05. In the model lymph node status (p < 0.05), metastases (p < 0.05), type of surgery (p < 0.01), age (p < 0.001), and education (p < 0.01) contribute to the explanation of the variance in general health perception. Conclusions: In the breast centers under investigation organizational characteristics of the hospital do not have an impact on primary breast cancer patients’ general health after hospital discharge. A possible reason is the high degree to which the treatment process itself is standardized. No significant financial relationships to disclose.

2018 ◽  
Author(s):  
M Banys-Paluchowski ◽  
K Milde-Langosch ◽  
T Fehm ◽  
I Witzel ◽  
L Oliveira-Ferrer ◽  
...  

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Jennifer K. Lang ◽  
Badri Karthikeyan ◽  
Adolfo Quiñones-Lombraña ◽  
Rachael Hageman Blair ◽  
Amy P. Early ◽  
...  

Abstract Background The CBR3 V244M single nucleotide polymorphism has been linked to the risk of anthracycline-related cardiomyopathy in survivors of childhood cancer. There have been limited prospective studies examining the impact of CBR3 V244M on the risk for anthracycline-related cardiotoxicity in adult cohorts. Objectives This study evaluated the presence of associations between CBR3 V244M genotype status and changes in echocardiographic parameters in breast cancer patients undergoing doxorubicin treatment. Methods We recruited 155 patients with breast cancer receiving treatment with doxorubicin (DOX) at Roswell Park Comprehensive Care Center (Buffalo, NY) to a prospective single arm observational pharmacogenetic study. Patients were genotyped for the CBR3 V244M variant. 92 patients received an echocardiogram at baseline (t0 month) and at 6 months (t6 months) of follow up after DOX treatment. Apical two-chamber and four-chamber echocardiographic images were used to calculate volumes and left ventricular ejection fraction (LVEF) using Simpson’s biplane rule by investigators blinded to all patient data. Volumetric indices were evaluated by normalizing the cardiac volumes to the body surface area (BSA). Results Breast cancer patients with CBR3 GG and AG genotypes both experienced a statistically significant reduction in LVEF at 6 months following initiation of DOX treatment for breast cancer compared with their pre-DOX baseline study. Patients homozygous for the CBR3 V244M G allele (CBR3 V244) exhibited a further statistically significant decrease in LVEF at 6 months following DOX therapy in comparison with patients with heterozygous AG genotype. We found no differences in age, pre-existing cardiac diseases associated with myocardial injury, cumulative DOX dose, or concurrent use of cardioprotective medication between CBR3 genotype groups. Conclusions CBR3 V244M genotype status is associated with changes in echocardiographic parameters suggestive of early anthracycline-related cardiomyopathy in subjects undergoing chemotherapy for breast cancer.


Author(s):  
Nils Martin Bruckmann ◽  
Julian Kirchner ◽  
Lale Umutlu ◽  
Wolfgang Peter Fendler ◽  
Robert Seifert ◽  
...  

Abstract Objectives To compare the diagnostic performance of [18F]FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Material and methods A cohort of 154 therapy-naive patients with newly diagnosed, histopathologically proven breast cancer was enrolled in this study prospectively. All patients underwent a whole-body [18F]FDG PET/MRI, computed tomography (CT) scan, and a bone scintigraphy prior to therapy. All datasets were evaluated regarding the presence of bone metastases. McNemar χ2 test was performed to compare sensitivity and specificity between the modalities. Results Forty-one bone metastases were present in 7/154 patients (4.5%). Both [18F]FDG PET/MRI and MRI alone were able to detect all of the patients with histopathologically proven bone metastases (sensitivity 100%; specificity 100%) and did not miss any of the 41 malignant lesions (sensitivity 100%). CT detected 5/7 patients (sensitivity 71.4%; specificity 98.6%) and 23/41 lesions (sensitivity 56.1%). Bone scintigraphy detected only 2/7 patients (sensitivity 28.6%) and 15/41 lesions (sensitivity 36.6%). Furthermore, CT and scintigraphy led to false-positive findings of bone metastases in 2 patients and in 1 patient, respectively. The sensitivity of PET/MRI and MRI alone was significantly better compared with CT (p < 0.01, difference 43.9%) and bone scintigraphy (p < 0.01, difference 63.4%). Conclusion [18F]FDG PET/MRI and MRI are significantly better than CT or bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. Both CT and bone scintigraphy show a substantially limited sensitivity in detection of bone metastases. Key Points • [18F]FDG PET/MRI and MRI alone are significantly superior to CT and bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. • Radiation-free whole-body MRI might serve as modality of choice in detection of bone metastases in breast cancer patients.


Sign in / Sign up

Export Citation Format

Share Document